Cover Image
市場調查報告書

ANCA相關血管炎 - 開發中產品分析

Anca Vasculitis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 321935
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
ANCA相關血管炎 - 開發中產品分析 Anca Vasculitis - Pipeline Review, H1 2016
出版日期: 2016年03月22日 內容資訊: 英文 59 Pages
簡介

ANCA相關血管炎是自體免疫造成的免疫性疾病,症狀有疲勞感、體重減輕、發燒、呼吸急促、關節痛、血痰、鼻血/血性鼻漏、鼻子潰瘍,聽障等。

本報告提供ANCA相關血管炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

ANCA相關血管炎概要

ANCA相關血管炎 - 治療藥的開發

  • 開發中產品:概要

開發中的治療藥:各企業

ANCA相關血管炎 - 開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

ANCA相關血管炎 - 開發中的產品:各企業

ANCA相關血管炎 - 開發治療藥的企業

  • ChemoCentryx, Inc.
  • GlaxoSmithKline plc
  • Kineta, Inc.

ANCA相關血管炎 - 治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • belimumab
  • CCX-1378
  • CCX-168
  • dalazatide
  • mepolizumab

ANCA相關血管炎 - 最新的開發平台(管線)資訊

ANCA相關血管炎 - 開發暫停中的計劃

ANCA相關血管炎 - 產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7795IDB

Summary

Global Markets Direct's, 'Anca Vasculitis - Pipeline Review, H1 2016', provides an overview of the Anca Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anca Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anca Vasculitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anca Vasculitis
  • The report reviews pipeline therapeutics for Anca Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anca Vasculitis therapeutics and enlists all their major and minor projects
  • The report assesses Anca Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anca Vasculitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anca Vasculitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anca Vasculitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anca Vasculitis Overview
  • Therapeutics Development
    • Pipeline Products for Anca Vasculitis - Overview
  • Anca Vasculitis - Therapeutics under Development by Companies
  • Anca Vasculitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Anca Vasculitis - Products under Development by Companies
  • Anca Vasculitis - Companies Involved in Therapeutics Development
    • ChemoCentryx, Inc.
    • GlaxoSmithKline Plc
    • Kineta, Inc.
  • Anca Vasculitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • belimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-1378 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mepolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anca Vasculitis - Recent Pipeline Updates
  • Anca Vasculitis - Dormant Projects
  • Anca Vasculitis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168
      • Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting
      • Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
      • Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements
      • Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis
      • Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anca Vasculitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Anca Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Anca Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Anca Vasculitis - Pipeline by Kineta, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Anca Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Anca Vasculitis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Anca Vasculitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top